Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Zentalis PharmaceuticalsZNTL | Open-market sale10b5-1 plan | 02/06–02/10 | 02/10 | 40,224 sh3 trades | $2.42avg. | $97,540.22 | −21.5% | |
Zentalis PharmaceuticalsZNTL | Open-market sale | 02/06–02/09 | 02/10 | 8,755 sh2 trades | $2.43avg. | $21,239.09 | −10.0% | |
Zentalis PharmaceuticalsZNTL | Open-market sale | 02/06–02/09 | 02/10 | 3,297 sh2 trades | $2.43avg. | $7,998.31 | −9.0% | |
Zentalis PharmaceuticalsZNTL | Open-market sale10b5-1 plan | 02/02–02/03 | 02/04 | 3,096 sh2 trades | $2.54avg. | $7,878.12 | −1.6% | |
Walters Group10% Owner | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/12/31 | 01/08 | 6,459,973 sh | $1.20 | $7,751,967.6 | +91.6% |
William Thurman Walters10% Owner | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/12/31 | 01/08 | 6,459,973 sh | $1.20 | $7,751,967.6 | +91.6% |
Susan Berkley Walters10% Owner | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/12/31 | 01/08 | 6,459,973 sh | $1.20 | $7,751,967.6 | +91.6% |
Matrix Capital Management Company10% Owner | Zentalis PharmaceuticalsZNTL | Open-market sale | 25/12/15 | 25/12/15 | 7,500,000 sh | $1.33 | $9,975,000 | −53.7% |
David E. Goel10% Owner | Zentalis PharmaceuticalsZNTL | Open-market sale | 25/12/15 | 25/12/15 | 7,500,000 sh | $1.33 | $9,975,000 | −53.7% |
Scott Dunseth MyersDirector | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/04/30 | 25/04/30 | 21,000 sh | $1.40 | $29,400 | +8.1% |
Ingmar BrunsChief Medical Officer | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/02/06 | 25/02/12 | 20,000 sh | $2.28 | $45,600 | +120.3% |
Mark LacknerChief Scientific Officer | Zentalis PharmaceuticalsZNTL | Open-market sale | 25/02/03 | 25/02/05 | 14,368 sh | $1.71 | $24,569.28 | −2.7% |
Andrea PaulChief Legal Officer | Zentalis PharmaceuticalsZNTL | Open-market sale | 25/02/03 | 25/02/05 | 13,230 sh | $1.71 | $22,623.3 | −1.2% |
Vincent VultaggioPAO and Interim PFO | Zentalis PharmaceuticalsZNTL | Open-market sale | 25/02/03 | 25/02/05 | 2,615 sh | $1.71 | $4,471.65 | −1.4% |
Julia Marie EastlandCEO & President | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/01/31 | 25/02/04 | 28,500 sh | $1.73 | $49,305 | No record |
Luke Nathaniel WalkerDirector | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/01/31 | 25/02/04 | 14,200 sh | $1.76 | $24,992 | +19.6% |
Jan SkvarkaDirector | Zentalis PharmaceuticalsZNTL | Open-market buy | 25/01/31 | 25/02/04 | 60,000 sh | $1.72 | $103,200 | +67.0% |
Mark LacknerChief Scientific Officer | Zentalis PharmaceuticalsZNTL | Open-market sale | 25/01/02 | 25/01/03 | 4,411 sh | $3.12 | $13,762.32 | −2.3% |
Vincent VultaggioPrincipal Accounting Officer | Zentalis PharmaceuticalsZNTL | Open-market sale10b5-1 plan | 24/10/04 | 24/10/04 | 1,603 sh | $3.18 | $5,097.54 | −4.5% |
Cam GallagherPresident, Interim CFO | Zentalis PharmaceuticalsZNTL | Open-market sale | 24/05/31 | 24/05/31 | 9,597 sh | $11.98 | $114,972.06 | −1.5% |